We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EVOX:NASDAQEvolution Global Acquisition Corp Analysis

Data as of 2026-06-17 - not real-time

$10.03

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Evolution Global Acquisition Corp (EVOX) is trading at $10.03, just above its 20‑day SMA of 10.02 and comfortably above the 50‑day SMA, indicating a short‑term bullish bias. The RSI sits at 59, suggesting momentum is still positive but not overbought, while the MACD histogram is slightly negative, hinting at a potential near‑term pullback. Volume is on an increasing trend and 30‑day volatility is modest at 1.46%, yet the stock’s beta is essentially zero, reflecting minimal correlation with broader market moves. The price is perched near the $9.98 support level with resistance around $10.06, and the Fear & Greed Index is in the “Extreme Greed” zone, implying heightened speculative interest.
The company has no operating revenue, negative book value per share, and zero earnings, characteristic of a blank‑check vehicle awaiting a merger. This lack of fundamentals, combined with extremely low daily volume (≈250 shares) and a high liquidity risk, makes the investment highly speculative. Without a disclosed target transaction, the upside hinges on a successful business combination, while the downside is limited to the support level and potential loss of capital.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Technical indicators show near‑term bearish divergence (MACD histogram)
  • Extremely low trading volume and high liquidity risk
  • Absence of any operating revenue or earnings

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Potential catalyst if a merger announcement materializes
  • Bullish price trend with support above $9.97
  • Continued speculative pressure reflected by extreme greed sentiment

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Uncertainty around future business combination and valuation
  • Negative book value and zero cash flow generation
  • Risk of prolonged illiquidity if no deal is completed

Key Metrics & Analysis

Financial Health

P/B Ratio-37.0
Op. Cash Flow$-526806
Industry P/E17.1

Technical Analysis

TrendBullish
RSI59.4
Support$9.98
Resistance$10.06
MA 20$10.02
MA 50$10.01
MA 200$9.97
MACDBearish
VolumeIncreasing
Fear & Greed Index92.13

Valuation

GradeOvervalued
TypeBlend

Risk Assessment

Beta0.01
Volatility1.46%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.